Semaglutide is a GLP-1 receptor agonist used in distinct products. A molecule name does not establish that every brand, formulation, or proposed use has the same approval.
Wegovy is a weight-management product; Ozempic’s cited EU record concerns type 2 diabetes. Brand names listed here are examples, not a complete global product inventory. Use the current information for the exact product and country.
STEP 1 evaluated injected semaglutide in adults without diabetes over 68 weeks. SELECT separately evaluated cardiovascular outcomes in adults with established cardiovascular disease and overweight or obesity without diabetes. The populations and outcomes should not be combined into a guaranteed personal result.
The US label includes contraindications and important warnings. This record neither reproduces every restriction nor provides dose conversions between formulations. A clinician and pharmacist should interpret the applicable product information.
Regulatory status checked on 3 October 2026
United States: Wegovy formulations are FDA-approved for specified uses. Higher-dose Wegovy HD was approved on 19 March 2026. Approval is formulation- and indication-specific; this record does not extend every use to all semaglutide brands.
European Union: EMA Wegovy record documents EU authorisation for weight management, with injection/tablet and age-specific restrictions. Ozempic has a separate diabetes product record.
Official records and primary evidence
- FDA-approved Wegovy prescribing information — Novo Nordisk / FDA-approved label
- FDA Wegovy supplemental approval letter — FDA
- EU Wegovy product record — EMA
- EU Ozempic product record — EMA
- STEP 1 original trial abstract — STEP 1 investigators / NEJM via NLM
- SELECT cardiovascular outcomes trial — SELECT investigators / NEJM via NLM
Route and frequency describe approved product records or clinical-trial protocols as identified above. They are not instructions to use, obtain, combine, or dose a medicine. This record is informational and has not been independently medically reviewed.